CO2023005883A2 - Procedimiento para la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}- 1-(difluorometil)-6-metil-1 4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona - Google Patents

Procedimiento para la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}- 1-(difluorometil)-6-metil-1 4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona

Info

Publication number
CO2023005883A2
CO2023005883A2 CONC2023/0005883A CO2023005883A CO2023005883A2 CO 2023005883 A2 CO2023005883 A2 CO 2023005883A2 CO 2023005883 A CO2023005883 A CO 2023005883A CO 2023005883 A2 CO2023005883 A2 CO 2023005883A2
Authority
CO
Colombia
Prior art keywords
chloro
metheno
pyrazolo
hexahydro
triazol
Prior art date
Application number
CONC2023/0005883A
Other languages
English (en)
Inventor
Nicolas Cuniere
Subha Mukherjee
William P Gallagher
Christopher Robert Jamison
Carolyn S Wei
Sergei Kolotuchin
Amarjit Singh
Chris Sfouggatakis
Adrian Ortiz
Steven R Wisniewski
Bin Zheng
Helen Y Luo
Sébastien François Emmanuel LEMAIRE
Haïm Cyril Ben
Kostiantyn Chernichenko
Diego Fernando Domenico Broggini
Simon Albert Wagschal
Duy Chi Trung Cao
Karl Reuter
Björn Schmalzbauer
Philipp Koschker
Martin D Eastgate
Dimitri Skliar
Alexander Zhdanko
Christos Xiouras
Matthew Penfield Mower
Ngoc Duc Tran
Ramdane Rahmani
Xavier Jean-Marie Jusseau
Kiran Matcha
Luca Alessandro Perego
Original Assignee
Bristol Myers Squibb Co
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Janssen Pharmaceutica Nv filed Critical Bristol Myers Squibb Co
Publication of CO2023005883A2 publication Critical patent/CO2023005883A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/72—Copper
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente solicitud se refiere en general a varios procesos para la preparación de (6R, 10S)-10-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-6-oxo-1(6H)-pirimidinil}-1-(difluorometil) -6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3 -b][1,7]diazaciclotetradecina-5(6H)-ona: Compuesto (I).
CONC2023/0005883A 2020-10-12 2023-05-08 Procedimiento para la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}- 1-(difluorometil)-6-metil-1 4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona CO2023005883A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063090558P 2020-10-12 2020-10-12
PCT/US2021/054413 WO2022081473A1 (en) 2020-10-12 2021-10-11 A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one

Publications (1)

Publication Number Publication Date
CO2023005883A2 true CO2023005883A2 (es) 2023-08-09

Family

ID=78536589

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0005883A CO2023005883A2 (es) 2020-10-12 2023-05-08 Procedimiento para la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}- 1-(difluorometil)-6-metil-1 4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona

Country Status (17)

Country Link
US (1) US20230416252A1 (es)
EP (1) EP4225757A1 (es)
JP (1) JP2023545129A (es)
KR (1) KR20230106611A (es)
CN (1) CN117120418A (es)
AR (1) AR123762A1 (es)
AU (1) AU2021360411A1 (es)
BR (1) BR112023006200A2 (es)
CA (1) CA3195024A1 (es)
CL (1) CL2023001049A1 (es)
CO (1) CO2023005883A2 (es)
IL (1) IL301889A (es)
MX (1) MX2023004237A (es)
PE (1) PE20231310A1 (es)
TW (1) TW202229280A (es)
UY (1) UY39469A (es)
WO (1) WO2022081473A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024030409A1 (en) 2022-08-01 2024-02-08 Bristol-Myers Squibb Company Use of milvexian for treating or preventing ischemic stroke

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (es) * 2014-10-01 2018-10-20
EP3953334B1 (en) * 2019-04-11 2023-11-22 Bristol-Myers Squibb Company Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one

Also Published As

Publication number Publication date
CN117120418A (zh) 2023-11-24
MX2023004237A (es) 2023-07-03
WO2022081473A1 (en) 2022-04-21
AR123762A1 (es) 2023-01-11
EP4225757A1 (en) 2023-08-16
CL2023001049A1 (es) 2023-09-22
AU2021360411A1 (en) 2023-06-08
BR112023006200A2 (pt) 2023-05-09
TW202229280A (zh) 2022-08-01
IL301889A (en) 2023-06-01
PE20231310A1 (es) 2023-08-24
JP2023545129A (ja) 2023-10-26
US20230416252A1 (en) 2023-12-28
UY39469A (es) 2022-04-29
KR20230106611A (ko) 2023-07-13
CA3195024A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
CO2023005883A2 (es) Procedimiento para la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}- 1-(difluorometil)-6-metil-1 4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona
PH12021551117A1 (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
PE20180050A1 (es) Heterociclos biciclicos como inhibidores de fgfr 4
CA2296031A1 (en) Novel spiroazabicyclic heterocyclic compounds
MX2016007371A (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
TW200833332A (en) New amino nicotinic and isonicotinic acid derivatives
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
NZ702041A (en) Heterocyclic containing entities, compositions and methods
UA84878C2 (ru) Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения
EA201991779A2 (ru) Способы получения ингибиторов jak киназ и родственных промежуточных соединений
PE20141408A1 (es) Aminoquinazolinas como inhibidores de quinasa
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
BR112022009390A2 (pt) Síntese melhorada de composto inibidor de kras g12c
YU94103A (sh) Novi derivati sulfonske kiseline
MX2019007452A (es) Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos.
AU2022200967A1 (en) Compositions and methods for treating infections
IL287102A (en) New synthetic possibilities towards the production of (6r, 10s) -10- {4- [5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl) phenyl] -6-oxo -1 (6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo [4,3-b] [1 , 7 ] diazacyclotetradecin-5 (6h)-one
WO2020127208A8 (en) Pharmaceutical process and intermediates
MX2021011389A (es) Compuestos de imidazolonilquinolina y usos terapeuticos de los mismos.
MY147637A (en) Quinoline derivatives as antibacterial agents
MY121793A (en) 2-phenylpyran-4-one derivatives
GEP20237531B (en) Monohydrate of rogaratinib hydrochloride and solid states thereof
HUP0303557A2 (hu) Eljárás és intermedierek cabergolin és származékai előállítására